drugset / Trial / NCT06005532
Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
RandomizedParallel-groupTriple-blindTreatment
Summary
MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®. The purpose of the study is to demonstrate efficacy, immunogenicity and safety of Adalimumab (manufactured by Mabscale, LLC) to Humira ® in adult patients with chronic plaque psoriasis of moderate and severe degree.
Timeline
- Start
- 2023-10-02
- Primary completion
- 2025-03
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | 0.4 ml | — |
| Comparator | Adalimumab | Monoclonal antibody | 0.8 ml | — |
| Comparator | Adalimumab | Monoclonal antibody | 40 mg | — |